Filing Details
- Accession Number:
- 0001209191-23-031295
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-19 21:20:00
- Reporting Period:
- 2023-01-11
- Accepted Time:
- 2023-05-19 21:20:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1348911 | Kalvista Pharmaceuticals Inc. | KALV | Pharmaceutical Preparations (2834) | 200915291 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1691102 | Christopher Yea | C/O Kalvista Pharmaceuticals, Inc 55 Cambridge Parkway, Suite 901E Cambridge MA 02142 | Chief Development Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-05-17 | 4,205 | $0.00 | 39,914 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-05-18 | 2,604 | $10.14 | 37,310 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Unit | Acquisiton | 2023-01-11 | 29,166 | $0.00 | 29,166 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2023-05-17 | 2,431 | $0.00 | 2,431 | $0.00 |
| Common Stock | Restricted Stock Unit | Disposition | 2023-05-17 | 1,774 | $0.00 | 1,774 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 29,166 | No | 4 | A | Direct | ||
| 24,305 | No | 4 | M | Direct | ||
| 21,285 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
- 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 17, 2022, subject to continued service through each vesting date.
Billionaire Hedge Funds
